This database contains 664 studies, archived under the term: "Randomised Controlled Trial"
Click here to filter this large number of results.
A pilot study using nabilone for symptomatic treatment in Huntington’s disease
Pilot study of nabilone in Huntington’s disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington’s Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = […]
Continuous positive airway pressure deepens sleep in patients with Alzheimer’s disease and obstructive sleep apnea
Cooke, Jana R.,
Ancoli-Israel, Sonia,
Liu, Lianqi,
Loredo, Jose S.,
Natarajan, Loki,
Palmer, Barton S.,
He, Feng,
Corey-Bloom, Jody
Objective: Patients with Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA.; Methods: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks […]
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial
Barnes, Deborah E.,
Yaffe, Kristine,
Belfor, Nataliya,
Jagust, William J.,
DeCarli, Charles,
Reed, Bruce R.,
Kramer, Joel H.
We performed a pilot randomized, controlled trial of intensive, computer-based cognitive training in 47 subjects with mild cognitive impairment. The intervention group performed exercises specifically designed to improve auditory processing speed and accuracy for 100 min/d, 5 d/wk for 6 weeks; the control group performed more passive computer activities (reading, listening, visuospatial game) for similar […]
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
Alvarez, X. Anton,
Sampedro, Carolina,
Cacabelos, Ramon,
Linares, Carlos,
Aleixandre, Manuel,
García-Fantini, Manuel,
Moessler, Herbert
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]
Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan
Homma, Akira,
Imai, Yukimichi,
Tago, Hisao,
Asada, Takashi,
Shigeta, Masahiro,
Iwamoto, Toshihiko,
Takita, Masashi,
Arimoto, Itaru,
Koma, Hiroshi,
Takase, Takao,
Ohbayashi, Toshio
Background/aims: A 6-month, randomized, double-blind, placebo-controlled study was extended to evaluate long-term safety and efficacy of donepezil in community-dwelling Japanese patients with severe Alzheimer’s disease (AD).; Methods: 189 patients were enrolled from the double-blind study into a 52-week, open-label extension study. After a 2- to 8-week washout, donepezil was escalated within 6 weeks to 10 […]
Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study
Hampel, Harald,
Ewers, Michael,
Bürger, Katharina,
Annas, Peter,
Mörtberg, Anette,
Bogstedt, Anna,
Frölich, Lutz,
Schröder, Johannes,
Schönknecht, Peter,
Riepe, Matthias W.,
Kraft, Inga,
Gasser, Thomas,
Leyhe, Thomas,
Möller, Hans-Jürgen,
Kurz, Alexander,
Basun, Hans
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer’s disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in […]
Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study
Gauthier, S.,
Aisen, P. S.,
Ferris, S. H.,
Saumier, D.,
Duong, A.,
Haine, D.,
Garceau, D.,
Suhy, J.,
Oh, J.,
Lau, W.,
Sampalis, J.
Objectives: The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer’s disease (AD), the Alphase study. Disease-modification was assessed using longitudinal volumetric MRI (vMRI) measurements of the hippocampus in a subgroup of patients. The present study describes the vMRI, cognitive […]
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Tierney, Mary C.,
Oh, Paul,
Moineddin, Rahim,
Greenblatt, Ellen M.,
Snow, W. Gary,
Fisher, Rory H.,
Iazzetta, John,
Hyslop, Peter St George,
MacLusky, Neil J.
We examined whether estradiol and norethindrone hormone therapy (HT) prevented decline in delayed verbal recall in older women with normal to mildly impaired memory functioning. This was a 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61-87, randomly assigned to receive 1 mg 17-beta estradiol daily and 0.35 mg norethindrone 3 days/week or daily […]
Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial
Yancheva, S.,
Ihl, R.,
Nikolova, G.,
Panayotov, P.,
Schlaefke, S.,
Hoerr, R.
Objective: This randomised, double-blind exploratory trial was undertaken to compare treatment effects and tolerability of EGb 761(R), donepezil and combined treatment in patients with AD and neuropsychiatric features.; Method: We enrolled 96 outpatients, aged 50 years or above, who met the NINCDS/ADRDA criteria for probable AD, scored below 36 on the TE4D, a screening test […]